Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Status:
Completed
Trial end date:
2020-08-07
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and
pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple
combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF
genotypes.